Answers are grounded in this paper and cite their sources.
Purpose: To characterize suprachoroidal space (SCS) changes after suprachoroidal triamcinolone acetonide (TA) injection for uveitic macular edema and their impact on clinical outcomes. Methods: We reviewed medical records and enhanced-depth optical coherence tomography (EDI-OCT) images from 67 patients receiving suprachoroidal TA injections for uveitic macular edema to assess SCS visibility and thickness before and at 1, 3, and 6 months after treatment. We collected best-recorded visual acuity (VA), central subfield thickness (CST), intraocular pressure (IOP), and subfoveal choroidal thickness (SFCT), then employed repeated measures ANOVA and linear regression to determine changes over time, and the association of SCS visibility or expansion with VA and CST outcomes after treatment. Results: In patients with uveitic macular edema (mean age 59.6 years), the SCS is visualized in 90.1% of eyes, with baseline SCS thickness of 18.5 ± 1.1 μm. The SCS expanded by 6.7±0.2μm and 4.8±0.02μm at 1 and 3 months after TA (P=0.0001-0.016), but returned to baseline at 6 months (P=0.350). CST improved at months 1 and 6 (P=0.002–0.009), respectively. A visible hyporeflective SCS layer was associated with greater CST improvements at 1 month (P=0.036) and less CST change at 6 months (P<0.001). Early SCS expansion at 1 month was also associated with worse CST outcomes at 6 months (R2=0.482, P=0.004). Conclusions: Eyes receiving suprachoroidal TA injections demonstrate macular SCS expansion on OCT, which may be associated with earlier anatomic improvements but less durability.
No takes yet. Share an insight, caveat, or question.
Sarabu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: